Anteris Technologies Ltd (ASX: AVR) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Anteris Technologies Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $372.93 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 18.09 million
Earnings per share -3.728
Dividend per share N/A
Year To Date Return 8.62%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Anteris Technologies Ltd (ASX: AVR)
    Latest News

    Five healthcare workers standing together and smiling.
    Healthcare Shares

    2 ASX healthcare shares bucking the trend to hit new highs on Friday

    These healthcare shares are on form on Friday

    Read more »

    a group of surgeons in full surgery dress including masks, gloves and head coverings stands together with arms folded and smiling eyes as if happy with the outcome of their efforts.
    Healthcare Shares

    Anteris (ASX:AVR) share price soars 22% on successful human trial

    The company's shares are off to a strong start this week.

    Read more »

    woman looking at iPhone whilst working on a laptop
    Share Fallers

    Why the Anteris (ASX:AVR) share price backtracked 6% today

    Anteris shares slide after news of an impending share dilution.

    Read more »

    Young doctor raising arms in air with hands in fists celebrating a new development
    Healthcare Shares

    Why is the Anteris (ASX:AVR) share price surging today?

    The Anteris Technologies Ltd (ASX: AVR) share price is rising today after the company announced its ComASUR Key Milestone report.

    Read more »

    falling healthcare asx share price Mesoblast capital raising
    Share Market News

    Anteris (ASX:AVR) share price drops 7% despite positive announcement

    The Anteris (ASX: AVR) share price has plunged 7.6% today despite a positive announcement from the medical company.

    Read more »

    Share Market News

    The Anteris (ASX:AVR) share price is down today but has soared 150% in 3 months

    The Anteris (ASX:AVR) share price exploded 150% higher over the past 3 months. Here's a summary of the latest results…

    Read more »

    investor looking excited at rising fortescue share price on laptop
    Share Market News

    Why the Anteris Technologies (ASX:AVR) share price soared 23% today

    The Anteris Technologies Ltd (ASX: AVR) share price rose an incredible 23% today after an online investor presentation yesterday.

    Read more »

    A boy with question mark on his forehead looking up as if watching an ASX share price
    Share Market News

    Why the Anteris (ASX:AVR) share price will be on watch today

    The Anteris Technologies (ASX:AVR) share price will be on watch this morning following the release of the company's latest results.

    Read more »

    Young doctor raising arms in air with hands in fists celebrating a new development
    Share Market News

    These 2 ASX healthcare shares popped today

    The All Ords is having a flat day but these 2 ASX healthcare shares have still managed to post some…

    Read more »

    soaring hydrix share price represented by doctor riding on top of heart high up in the clouds
    Share Market News

    Why the Anteris (ASX:AVR) share price is edging higher today

    The Anteris Technologies Ltd (ASX: ANV) share price is edging higher today after releasing the results from its anti-clarification study.

    Read more »

    a woman
    Record Highs

    Twiggy Forrest backed Invex Therapeutics has now doubled since its IPO

    Have you got as much cash to burn as Andrew Forrest?

    Read more »

    a woman
    Share Fallers

    Why the Admedus share price is sinking again on more big losses

    Admedus Ltd (ASX:AHZ) has been a sorry tale for shareholders.

    Read more »

    AVR ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Anteris Technologies Ltd

    Anteris Technologies Ltd is a structural heart company engaged in delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. The group's solutions include Anteris' DurAVR transcatheter heart valve for younger patients who need a heart valve that will last their lifetime, as well as DurAVR with its biomimetic design that replicates the normal blood flow of a healthy human aortic valve. The company derives key revenue from Australia and the U.S.

    AVR Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    15 Mar 2024 $20.80 $0.30 1.46% 2,705 $20.75 $20.99 $20.75
    14 Mar 2024 $20.50 $-0.40 -1.91% 14,447 $20.90 $21.14 $20.50
    13 Mar 2024 $20.90 $0.90 4.50% 209,761 $20.00 $21.00 $20.00
    12 Mar 2024 $20.00 $0.80 4.17% 10,783 $19.39 $20.00 $19.11
    11 Mar 2024 $19.20 $0.19 1.00% 9,161 $19.00 $19.20 $18.90
    08 Mar 2024 $19.01 $0.01 0.05% 12,310 $19.20 $19.31 $18.80
    07 Mar 2024 $19.00 $0.20 1.06% 23,771 $18.90 $19.30 $18.75
    06 Mar 2024 $18.80 $0.80 4.44% 16,047 $18.00 $18.80 $17.81
    05 Mar 2024 $18.00 $0.60 3.45% 14,415 $17.40 $18.00 $17.40
    04 Mar 2024 $17.40 $0.15 0.87% 5,863 $17.10 $17.40 $17.05
    01 Mar 2024 $17.25 $0.25 1.47% 6,813 $17.00 $17.25 $16.95
    29 Feb 2024 $17.00 $-0.50 -2.86% 10,534 $17.00 $17.20 $16.90
    28 Feb 2024 $17.50 $0.30 1.74% 71,811 $16.95 $17.50 $16.95
    27 Feb 2024 $17.20 $0.00 0.00% 12,719 $17.20 $17.20 $16.86
    26 Feb 2024 $17.20 $0.30 1.78% 24,003 $16.90 $17.40 $16.89
    23 Feb 2024 $16.90 $0.08 0.48% 8,290 $16.70 $16.91 $16.70
    22 Feb 2024 $16.82 $-0.08 -0.47% 10,365 $16.90 $16.90 $16.57
    21 Feb 2024 $16.90 $-0.09 -0.53% 9,192 $16.71 $16.90 $16.44
    20 Feb 2024 $16.99 $-0.01 -0.06% 8,814 $17.09 $17.09 $16.68
    19 Feb 2024 $17.00 $0.10 0.59% 35,083 $17.00 $17.30 $16.80

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    15 Sep 2023 Stephen (Steve) Denaro Issued 80,500 $1,634,150
    Issue of options.
    15 Sep 2023 John Seaberg Issued 157,500 $3,197,250
    Issue of options.
    15 Sep 2023 Wenyi Gu Issued 80,500 $1,634,150
    Issue of options.
    15 Sep 2023 Wayne Paterson Issued 700,000 $14,210,000
    Issue of options.
    31 May 2023 Wayne Paterson Issued 4,167 $100,008
    Issue of securities. As per announcement on 01-06-2023
    31 May 2023 Wayne Paterson Issued 4,167 $99,174
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Stephen (Steve) Denaro Company SecretaryNon-Executive Director Oct 2018
    Mr Denaro was appointed as Non-Executive Director and Company Secretary on 31 October 2018. Mr Denaro has more than 30 years of senior level and Board level experience across publiclylisted companies; serving as Chief Financial Officer, Company Secretary and Director. He brings experience in managing compliance with finance and accounting regulatory requirements. He has managed investment acquisitions and subsequent funding (domestic and international). Mr Denaro is a resident of Brisbane, QLD, Australia.
    Mr John Seaberg Non-Executive DirectorNon-Executive Chairman Oct 2014
    Mr Seaberg has been an independent Non-Executive Director of Anteris Technologies Ltd since 10 October 2014. He was appointed as Deputy Chair on 16 June 2016 and Chair on 14 March 2017. From 2008 until its sale to Baxter in 2012, Mr Seaberg served as Chair of the Board of Synovis Inc (NASDAQ:SYNO), a Minneapolis based manufacturer of various medical devices and bio scaffold tissue products. From 2007 until 2014 he was Founder, Chair and CEO of NeoChord Inc., a venture capital-backed company commercialising technology developed at the Mayo Clinic for the repair of the mitral valve via minimally invasive techniques. From 1996 to 2006, Mr Seaberg served at Guidant Corp (subsequently acquired by Boston Scientific Corp) where he served in various executive level positions including Director of Bradycardia Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery and Vice President of Sales for Cardiac Rhythm Management. In 1991, Mr Seaberg was co-founder of ACIST Medical and served as its first President and CEO. Mr Seaberg is a resident of Minneapolis, Minnesota, United States of America. He is a member of Risk Management Committee.
    Mr Wayne Paterson Managing DirectorChief Executive Officer Feb 2016
    Mr Paterson has been a Director of Anteris Technologies Ltd since 10 October 2014. Mr Paterson has held numerous senior positions in multi-national pharmaceutical companies and has lived in seven countries during the past 20 plus years. Throughout his career, he has been responsible for building and managing multi-billion dollar businesses throughout the world, including mergers, integrations, acquisitions and major restructures as President and CEO. From 2005 to 2013 Mr Paterson held senior positions at Merck KGaA, most recently as President of Europe, Canada and Australia. Prior to this, Mr Paterson was President of Emerging Markets, President of Japan and Global Head of Cardiovascular Medicine. Between 1999 and 2005, Mr Paterson served at Roche Pharmaceuticals where he was most recently Head of Pharmaceuticals in Roche's South Korean operation. He also served as Head of Commercial Operations for Roche China based in Shanghai. Mr Paterson is an Australian national and resides in Minneapolis, Minnesota, United States of America.
    Dr Wenyi Gu Non-Executive Director Oct 2018
    Dr Gu currently works as Research Fellow for the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland (UQ), where he began his post-doctoral work in 2001. He held a Peter Doherty Fellowship (2006-2009) and was supported by the National Health and Medical Research Council (NHMRC) to work at Harvard Medical School, Harvard University as a visiting research fellow. Before engaging in nanomedicine (focusing on drug delivery and cancer therapy), he worked on RNAi-based gene therapy for several years at Translation Research Institute (TRI). Dr Gu's research has been published in respected industry journals such as Nature Communications, Ad. Materials, ACS Nano and PNAS USA. Dr Gu is a resident of Brisbane, QLD, Australia.
    Mr Matthew McDonnell Chief Financial Officer
    -
    Mr David St Denis Chief Operating Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Perceptive Life Sciences Master Fund Ltd 1,840,000 11.98%
    Hsbc Custody Nominees (Australia) Limited A/C 2 1,043,353 6.79%
    Hsbc Custody Nominees (Australia) Limited Gsco Eca 633,164 4.12%
    J P Morgan Nominees Australia Pty Limited 561,484 3.66%
    Citicorp Nominees Pty Limited 548,442 3.57%
    Hunter Capital Advisors P/L 478,991 3.12%
    Hsbc Custody Nominees (Australia) Limited 382,689 2.49%
    Mutual Trust Pty Ltd 335,689 2.19%
    Hsbc Custody Nominees (Australia) Limited Gsi Eda 322,259 2.10%
    Mr Patrick Chew 314,555 2.05%
    Mr Ricky Steven Neumann 310,774 2.02%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 290,864 1.89%
    Bnp Paribas Noms Pty Ltd <Global Markets Drp> 256,009 1.67%
    Evolution Capital Pty Ltd 247,522 1.61%
    Bnp Paribas Noms Pty Ltd <Drp> 177,132 1.15%
    Merrill Lynch (Australia) Nominees Pty Limited 146,791 0.96%
    Amedan Pty Ltd 138,700 0.90%
    Mishtalem Pty Ltd 134,000 0.87%
    Mr David Lamm 125,000 0.81%
    Dr Gary Owen Rooke 120,000 0.78%

    Profile

    since

    Note